« Return to News | CROs/Service Providers

SGS acquires Vitrology

Wednesday, May 23, 2012 10:29 AM

SGS, a Swiss inspection, verification, testing and certification company, has decided to acquire Vitrology, a biopharmaceutical contract testing organization based in Glasgow, U.K.

“Building upon our biologic therapeutics strategy and following our recent successful M-Scan acquisition, Vitrology now complements the services provided by SGS,” said Chris Kirk, CEO of SGS. “It creates an ideal platform for further deployment in virology and molecular biology, to be leveraged within our Life Science global network.”

At its state-of-the-art GLP/cGMP (Good Laboratory Practices/current Good Manufacturing Practices) laboratory facility, Vitrology provides a comprehensive range of biosafety services such as virology, cell and molecular biology as well as microbiology and electron microscopy. Founded in 2007, privately owned and backed by Archangel Informal Investment, Vitrology has 38 employees with sales agents in North America and Asia. In 2011, it generated revenue in excess of $4.7 million.

Financial terms of the agreement were not disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.